Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire E Wainwright

Showing results (61-70 of 96) with videos related to

Pageof 10
Sort By:
American Journal of Respiratory and Critical Care Medicine|April 18, 2013
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationJane C Davies, Claire E Wainwright, Gerard J Canny, et al.
Thorax|January 25, 2013
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of ageCatherine Ann Byrnes, Suzanna Vidmar, Joyce L Cheney, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2018
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis PatientsLois W Martin, Cynthia L Robson, Annabelle M Watts, et al.
BMC Infectious Diseases|June 7, 2014
A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosisMelanie W Syrmis, Timothy J Kidd, Ralf J Moser, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Thorax|April 30, 2021
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosisKatie J Bayfield, Tonia A Douglas, Tim Rosenow, et al.
The European Respiratory Journal|August 11, 2012
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centresTimothy J Kidd, Kay A Ramsay, Honghua Hu, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 28, 2022
Factors in childhood associated with lung function decline to adolescence in cystic fibrosisNelufa Begum, Catherine A Byrnes, Joyce Cheney, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2025
Progression of structural lung disease and lung function in adolescents with cystic fibrosisYuxin Chen, Daan Caudri, Eleni-Rosalina Andrinopoulou, et al.
Thorax|April 19, 2014
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosisLuke D Knibbs, Graham R Johnson, Timothy J Kidd, et al.
Pageof 10

Showing results (61-70 of 96) with videos related to

Sort By:
Pageof 10
American Journal of Respiratory and Critical Care Medicine|April 18, 2013
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutationJane C Davies, Claire E Wainwright, Gerard J Canny, et al.
Thorax|January 25, 2013
Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of ageCatherine Ann Byrnes, Suzanna Vidmar, Joyce L Cheney, et al.
Antimicrobial Agents and Chemotherapy|September 12, 2018
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis PatientsLois W Martin, Cynthia L Robson, Annabelle M Watts, et al.
BMC Infectious Diseases|June 7, 2014
A comparison of two informative SNP-based strategies for typing Pseudomonas aeruginosa isolates from patients with cystic fibrosisMelanie W Syrmis, Timothy J Kidd, Ralf J Moser, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Thorax|April 30, 2021
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosisKatie J Bayfield, Tonia A Douglas, Tim Rosenow, et al.
The European Respiratory Journal|August 11, 2012
Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centresTimothy J Kidd, Kay A Ramsay, Honghua Hu, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|March 28, 2022
Factors in childhood associated with lung function decline to adolescence in cystic fibrosisNelufa Begum, Catherine A Byrnes, Joyce Cheney, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 24, 2025
Progression of structural lung disease and lung function in adolescents with cystic fibrosisYuxin Chen, Daan Caudri, Eleni-Rosalina Andrinopoulou, et al.
Thorax|April 19, 2014
Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosisLuke D Knibbs, Graham R Johnson, Timothy J Kidd, et al.
Pageof 10